대한의생명과학회지 (Biomedical Science Letters)

  • 제24권3호
  • /
  • Pages.157-167
  • /
  • 2018
  • /
  • 1738-3226(pISSN)
  • /
  • 2288-7415(eISSN)
대한의생명과학회 (The Korean Society for Biomedical Laboratory Sciences)
권호 표지
DOI QR코드

DOI QR Code

Current Status of the Clinical Development of Gene Therapy

  • Kwon, Sun-Il (Department of Biomedical Laboratory Science, Deagu Health Science University)
  • 투고 : 2018.07.10
  • 심사 : 2018.09.04
  • 발행 : 2018.09.30
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

The concept of gene therapy is to treat a disease by transferring therapeutic nucleic acids to a patient's cells. It took several decades from the basic theoretical proposal of gene therapy to the current promising treatment option for some important human diseases. The encountered adverse effects in the early clinical studies boosted the development of sophisticated vectors and elaborate clinical designs. The gene therapy is now considered to have the potential to cure many diseases that are incurable with conventional medications. By the end of 2017, about 2,600 clinical trials of gene therapy have been performed or are ongoing for a variety of diseases such as cancers, monogenic diseases, cardiovascular diseases and neurological diseases etc. Here, we present a brief introduction of technical achievement in relation to gene therapy development, and a review of the current status of global gene therapy clinical development.

키워드

참고문헌

  1. Abbasi J. Biotech Innovations. Clinical Advances in Human Gene Therapies. JAMA. 2018. 319: 113.
  2. Ameri H. Prospect of retinal gene therapy following commercialization of voretigene neparvovec-rzyl for retinal dystrophy mediated by RPE65 mutation. J Curr Ophthalmol. 2018. 30: 1-2. https://doi.org/10.1016/j.joco.2018.01.006
  3. Blaese RM, Culver KW, Miller AD, Carter CS, Fleisher T, Clerici M, Shearer G, Chang L, Chiang Y, Tolstoshev P, Greenblatt JJ, Rosenberg SA, Klein H, Berger M, Mullen CA, Ramsey WJ, Muul L, Morgan RA, Anderson WF. T lymphocyte-directed gene therapy for ADA- SCID: initial trial results after 4 years. Science. 1995. 270: 475-480. https://doi.org/10.1126/science.270.5235.475
  4. Choi JW. What is virus to cancer? Two strategies to treat cancers. Opinion. Biospectator. 18 Jul 2017.
  5. ClinicalTrials.gov homepage (ClinicalTrials.gov is a database of privately and publicly funded clinical studies conducted around the world.). retrieved on 27 Jun 2018. https://www.clinicaltrials.- gov/ct2/results?term=cancer&cond=gene+therapy&strd_s=01%2F01%2F2010&strd_e=06%2F25%2F2017&age_v=&gndr=&type=&rslt=&phase=1&Search=Apply
  6. Conry RM, Westbrook B, McKee S, Norwood TG. Talimogene laherparepvec: First in class oncolytic virotherapy. Hum Vaccin Immunother. 2018. 14: 839-846. https://doi.org/10.1080/21645515.2017.1412896
  7. Dunbar CE, High KA, Joung JK, Kohn DB, Ozawa K, Sadelain M. Gene therapy comes of age. Science. 2018. 359: 1-10.
  8. European Medicines Agency homepage. Human regulatory, Scien- tific guidelines, multidisplinary, Gene therapy. retrieved on 27 Jun 2018. http://www.ema.europa.eu/ema/index.jsp?curl=-pages/regulation/general/general_content_000410.jsp&mid= WC0b01ac058002958d
  9. Friedmann T, Roblin R. "Gene therapy for human genetic disease?". Science. 1972. 175: 949-955. https://doi.org/10.1126/science.175.4025.949
  10. Gene Therapy Clinicla Trials Worldwide homepage. The Journal of Gene Medicine. updated Nov. 2017. retrieved on 27 Jun 2018. http://www.abedia.com/wiley/index.html
  11. Hong SW, Seo SK, Ryu SY, Uhm JH, Kim SH, Baek JH, Kim H, Lee BY, Moon KS, Park KL, Oh YK, Choi BH, Kim JY, Clinical research trend in gene therapy. Dept of Advanced Bio product, National Institute of Food and Drug Safety Evaluation. 31 May 2016.
  12. Korean FDA homepage. Legal Data. Legal Information. Guide line for Officers. Guideline for Civil Petitioners. Gene Therapy. http://www.mfds.go.kr/ index.do. retrieved on 27 Jun 2018.
  13. Lee TG. Latest trend of gene therapy. Home page of Korean Drug Development Fund. Trend of new drug development> Archive> Trend of new drug development. Expert Opinion. 6 Feb 2017a.
  14. Lee HK. Norvatis, The first US FDA-approved CAR-T, Kymriah. The start of new paradigm in the approval of new medicine to treat acute leukemia. Medical News. 31 Aug 2017b.
  15. Lee HK. US FDA, Approval of Luxturna, treatment for acute genetic retina diseases, Single dose gene therapy, scheduled to launch next year. Medical News. 20 Dec 2017c.
  16. Lee HM. Methods and research trend of gene therapy. BRIC View. 2016. T22: 1-17.
  17. Liu Y, Chen X, Han W, Zhang Y. Tisagenlecleucel, an approved anti-CD19 chimeric antigen receptor T-cell therapy for the treatment of leukemia. Drugs Today (Barc). 2017. 53: 597-608. https://doi.org/10.1358/dot.2017.53.11.2725754
  18. Park DY. Dr. Bryan of US FDA said "Gene therapy development, Try to hit a homer" MediGate News. 28 Jun 2018.
  19. Paton DM. Nusinersen: antisense oligonucleotide to increase SMN protein production in spinal muscular atrophy. Drugs Today (Barc). 2017. 53: 327-337. https://doi.org/10.1358/dot.2017.53.6.2652413
  20. Pawliuk R, Westerman KA, Fabry ME, Payen E, Tighe R, Bouhassira EE, Acharya SA, Ellis J, London IM, Eaves CJ, Humphries RK, Beuzard Y, Nagel RL, Leboulch P. Correction of sickle cell disease in transgenic mouse models by gene therapy. Science. 2001. 294: 2368-2371. https://doi.org/10.1126/science.1065806
  21. Peters R, Harris T. Advances and innovations in haemophilia treatment, Reviews. Nature Reviews Drug Discovery. 2018. 17: 493-508. https://doi.org/10.1038/nrd.2018.70
  22. Philippidis A. 25 Up and Coming Gene Therapies. The Lists, Invest- ment, Incentives, and IP Drive Growth in Clinical Development. Genetic and Biotechnology News. 07 May, 2018.
  23. PubMed homepage. retrieved on 27 June 2018. www.ncbi.nlm.nih.gov/pubmed
  24. Roberts ZJ, Better M, Bot A, Roberts MR, Ribas A. Axicabtagene ciloleucel, a first-in-class CAR T cell therapy for aggressive NHL. Leuk Lymphoma. 2017. 23: 1-12.
  25. Saudemont A, Jespers L, Clay T. Current Status of Gene Engineering Cell Therapeutics. Front Immunol. 2018. 9: 153. https://doi.org/10.3389/fimmu.2018.00153
  26. Saudemont A, Jespers L, Clay T. Current Status of Gene Engineering Cell Therapeutics. Front Immunol. 2018. 9: 153. https://doi.org/10.3389/fimmu.2018.00153
  27. Seo KW, Seo SK, Ruy SL, Uhm JH, Lee BY, Kim BC, Baek JH, Kim H, Oh YK, Choi BH, Kim JY, Park KL, Moon KS. Trend of R&D and regulation of gene therapy. Dept of Advanced Bio product, National Institute of Food and Drug Safety Evaluation. 30 Dec 2015.
  28. Spinraza home page. retrieved on 27 June 2018. https://www.-spinraza.com/.
  29. Stirnadel-Farrant H, Kudari M, Garman N, Imrie J, Chopra B, Giannelli S, Gabaldo M, Corti A, Zancan S, Aiuti A, Cicalese MP, Batta R, Appleby J, Davinelli M, Ng P. Gene therapy in rare diseases: the benefits and challenges of developing a patient-centric registry for Strimvelis in ADA-SCID. Orphanet J Rare Dis. 2018. 13: 49. https://doi.org/10.1186/s13023-018-0791-9
  30. Terry M. Gottlieb at BIO 2018: 40 Gene Therapy Approvals by 2022. Biospace. 07 Jun, 2018.
  31. Tosolini AP, Smith GM. Editorial: Gene Therapy for the Central and Peripheral Nervous System. Front Mol Neurosci. 2018. 11: article 54.
  32. Trojan J, Johnson TR, Rudin SD, Ilan J, Tykocinski ML, Ilan J. "Treatment and prevention of rat glioblastoma by immunogenic C6 cells expressing antisense insulin-like growth factor I RNA". Science. 1993. 259: 94-97. https://doi.org/10.1126/science.8418502
  33. US FDA homepage. Vaccines, Blood & Biologics, Cellular & Gene Therapy Guidance Documents. retrieved on 27 Jun 2018. https://www.fda.gov/BiologicsBloodVaccines/Guidance-ComplianceRegulatoryInformation/Guidances/Cellularand GeneTherapy/default.htm
  34. Warner E. Goodbye Glybera! The World's First Gene Therapy will be Withdrawn. Labbiotech.eu. 20/04/2017. retrieved on 27 Jun 2018. https://labiotech.eu/uniqure-glybera-marketing-withdrawn/